Evaluating secukinumab's effectiveness with surgery for hidradenitis suppurativa
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice
This study is testing if using secukinumab along with surgery can help people with moderate to severe hidradenitis suppurativa feel better and have fewer problems after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | N/A to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Academic / other |
| Drugs / interventions | secukinumab |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06926192 on ClinicalTrials.gov |
What this trial studies
This study aims to retrospectively analyze the efficacy and safety of secukinumab when used in conjunction with surgical treatment for moderate to severe hidradenitis suppurativa (HS). It focuses on patients aged 18 to 80 years who have been diagnosed with HS and have undergone surgery while receiving secukinumab. The research seeks to provide real-world evidence on the treatment outcomes and safety profile of this combination therapy, addressing the limitations of traditional treatments and the high recurrence rates associated with surgery alone.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 80 with moderate to severe hidradenitis suppurativa confirmed by histopathological examination.
Not a fit: Patients who have received additional adjuvant therapy during the follow-up period or those lost to follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes and quality of life for patients suffering from moderate to severe hidradenitis suppurativa.
How similar studies have performed: While the use of biologic agents like TNF-α inhibitors has shown promise, the specific combination of secukinumab with surgery for HS is still being evaluated and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS 2. The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital 3. Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital 4. Patients with complete clinical data followed up for at least 1 year Exclusion Criteria: 1. Patients lost to follow-up 2. Patients with less than one year of follow-up 3. Patients who received additional adjuvant therapy during the follow-up period
Where this trial is running
Nanjing, Jiangsu
- Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Youjun ZHENG
- Email: 19943909917@163.com
- Phone: 1+86 9943909917
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.